2378 completed, 814 unknown, 699 recruiting, 497 terminated. 1474 Phase 2, 1250 Phase 1, 1077 Not applicable, 422 Phase 3, 198 Phase 4.
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer | Not applicable | Not yet recruiting | Oncare Madrid | 32 | 2028-05-01 | 2026-10-08 |
| Effect of Betadine Vaginal Cleansing Before Cesarean Section to Reduce Postoperative Infectious Morbidity Povidone-iodine 5% solution - Cesarean Section, Surgical Site Infection | Not applicable | Not yet recruiting | Mohamed Mousa Mohamed Mousa | 600 | 2027-05-01 | 2026-07-20 |
| PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing | Not applicable | Not yet recruiting | Rachel Miller | 200 | 2027-04-01 | 2026-09-10 |
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial Time-restricted eating - Polycystic Ovary Syndrome | Not applicable | Not yet recruiting | Joanna Bajerska | 84 | 2027-01-09 | 2026-10-16 |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome Synbiotic Supplement, Placebo - PCOS (Polycystic Ovary Syndrome) | Not applicable | Recruiting | Atlas University | 32 | 2026-12-20 | 2026-10-28 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot Ketogenic diet, Exogenous Ketone Supplement - PCOS (Polycystic Ovary Syndrome) | Not applicable | Recruiting | Ohio State University | 40 | 2026-12-01 | 2026-05-08 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| Safety in Ovarian Cancer for Average-Risk Women - Analysis Blood-Based Ovarian Cancer Screening Test - Ovarian Cancer | Not applicable | Not yet recruiting | Mercy BioAnalytics, Inc. | 1750 | 2026-11-01 | 2026-10-16 |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
| AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery Ovarian Cancer, Ovarian Tumor | Not yet recruiting | Catharina Ziekenhuis Eindhoven | 1300 | 2026-11-01 | 2026-10-20 | |
| Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks No intervention; observational assessment only - Obesity & Overweight, Diabetes Mellitus, Type 2 | Not yet recruiting | Shanxi Bethune Hospital | 25974 | 2026-11-01 | 2026-10-21 | |
| Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors Web-Based Ovarian Cancer Awareness Education, General Reproductive Health Information - Ovarian Cancer | Not applicable | Not yet recruiting | Ege University | 82 | 2026-11-01 | 2026-10-22 |
| Oral GDC-0077 in Premature Ovarian Insufficiency GDC-0077 - Primary Ovarian Insufficiency | Phase 1 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 12 | 2026-10-30 | 2026-10-29 |
| Phase 1 Study of VT-101 in Advanced Ovarian Cancer VT-101 - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 1 | Not yet recruiting | Michael J. Goodheart | 22 | 2026-10-23 | 2026-10-29 |
Showing 20 of 5094. Sign in to see all of them.
Ovarian Neoplasms (3262) · Polycystic Ovary Syndrome (951) · Fallopian Tube Neoplasms (828) · Carcinoma, Ovarian Epithelial (785) · Breast Neoplasms (687) · Endometrial Neoplasms (457) · Neoplasms (374) · Uterine Cervical Neoplasms (366) · Carcinoma, Non-Small-Cell Lung (341) · Pancreatic Neoplasms (327) · Colorectal Neoplasms (321) · Stomach Neoplasms (269) · Prostatic Neoplasms (257) · Lung Neoplasms (254) · Melanoma (213)
Female Urogenital Diseases (5093) · Female Urogenital Diseases and Pregnancy Complications (5093) · Genital Diseases (5093) · Urogenital Diseases (5093) · Genital Diseases, Female (5078) · Gonadal Disorders (4952) · Endocrine System Diseases (4944) · Ovarian Diseases (4923) · Neoplasms (4372) · Neoplasms by Site (3727) · Urogenital Neoplasms (3717) · Genital Neoplasms, Female (3702) · Endocrine Gland Neoplasms (3664) · Neoplasms by Histologic Type (1455)
Paclitaxel (388) · Carboplatin (383) · Bevacizumab (212) · Metformin (168) · liposomal doxorubicin (122) · Gemcitabine (121) · pembrolizumab (121) · Cisplatin (110) · Cyclophosphamide (106) · olaparib (104) · Topotecan (103) · Taxes (75) · niraparib (75) · Letrozole (67) · Clomiphene (63)
National Cancer Institute (NCI) (194) · M.D. Anderson Cancer Center (88) · Memorial Sloan Kettering Cancer Center (85) · Gynecologic Oncology Group (78) · AstraZeneca (66) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (46) · Cairo University (39) · Dana-Farber Cancer Institute (37) · Mayo Clinic (32) · Eli Lilly and Company (31) · University of Virginia (31) · Pfizer (29) · University Health Network, Toronto (28) · AbbVie (27) · City of Hope Medical Center (26)
United States (2295) · China (565) · France (358) · Italy (344) · United Kingdom (328) · Canada (325) · Spain (311) · Germany (223) · Belgium (220) · Australia (196) · South Korea (194) · Egypt (153) · Netherlands (151) · Turkey (Türkiye) (136) · Japan (128)
Lei Li, M.D. (14) · Stefano Palomba, MD (14) · Paul Sabbatini, MD (13) · Francesco Orio, MD (10)
PMID 37185961, PMID 37407274, PMID 35170751, PMID 27008889, PMID 37462232, PMID 39695768, PMID 19238149, PMID 30633128, PMID 16394300, PMID 20818904, PMID 23922302, PMID 26961146, PMID 29342393, PMID 29486615, PMID 32379297, PMID 35537408, PMID 36512649, PMID 39019698, PMID 41868592, PMID 42693220, PMID 14688154, PMID 18158291, PMID 20424285, PMID 21324454, PMID 21941283, PMID 24637997, PMID 26707054, PMID 30796792, PMID 31547562, PMID 32195207, PMID 32335895, PMID 33347618, PMID 33538338, PMID 34904813, PMID 35262624, PMID 35397664, PMID 40132910, PMID 40785326, PMID 41044356, PMID 42014131, PMID 12826431, PMID 16239238, PMID 16882940, PMID 16966687, PMID 17000396, PMID 17949799, PMID 18024865, PMID 18480812, PMID 19282241, PMID 19427025
U10CA027469 (59), U10CA180868 (47), 2023 (36), 2018 (25), 2025 (23), 2016 (18), 2017 (18), P30CA033572 (18), 2008 (16), 2015 (16), 2009 (15), P30CA015083 (14), U10CA101165 (12), 2019 (11), P30CA016672 (11)